Edition:
United Kingdom

Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

662.10GBp
18 Feb 2019
Change (% chg)

-- (--)
Prev Close
662.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
89,558
52-wk High
1,064.38
52-wk Low
511.00

Latest Key Developments (Source: Significant Developments)

Oxford Biomedica Provides An Update On Programmes Outlicensed To Sanofi
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Oxford BioMedica PLC ::UPDATE ON PROGRAMMES OUTLICENSED TO SANOFI.SANOFI HAS CONFIRMED THAT IT WILL CONTINUE WITH ITS ONGOING PHASE I/II PROOF-OF-CONCEPT STUDY WITH SAR422459.SANOFI INTENDS TO SEEK A NEW PARTNER FOR OXB'S OUTLICENSED OPHTHALMOLOGY GENE THERAPIES.SANOFI WILL NOT CONTINUE TO DEVELOP SAR421869.SANOFI IS CURRENTLY IN DISCUSSIONS WITH POTENTIAL EXTERNAL PARTNERS TO CONTINUE FURTHER DEVELOPMENT OF BOTH OF THESE PROGRAMMES.  Full Article

Oxford Biomedica Says HY Gross Income Growth Of 118 Pct To 36 Mln Stg
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Oxford BioMedica PLC ::HY GROSS INCOME GROWTH OF 118 PERCENT TO £36.0 MILLION.HY LICENCE INCOME OF £18.3 MILLION RECOGNISED SEGMENTED BY PRODUCT (£10.2 MILLION) AND PLATFORM (£8.1 MILLION).  Full Article

Oxford Biomedica Says European Commission Approved Novartis Car-T Cell Therapy
Tuesday, 28 Aug 2018 

Aug 28 (Reuters) - Oxford BioMedica PLC ::NOTES THAT EUROPEAN COMMISSION (EC) HAS APPROVED NOVARTIS CAR-T CELL THERAPY, KYMRIAH.  Full Article

BRIEF-Oxford BioMedica Notes Longer-Term Analyses From Pivotal Kymriah Trials

* NOTES AN ANNOUNCEMENT BY NOVARTIS ON LONGER-TERM ANALYSES OF BOTH ELIANA AND JULIET PIVOTAL TRIALS